No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Innocan Pharma Provides Its Annual "State of Research and Development" Update for 2024
Press Release: Innocan Pharma Reports Third Quarter 2024 Financial Results
Innocan Pharma Submits Investigational New Animal Drug Application to FDA's Veterinary Center
Innocan Pharma Engages Pain-Management Expert Ahead of FDA Meeting
Innocan Pharma Announces Successful Preliminary Safety Evaluation of LPT-CBD in Minipigs
CBD-Focused Innocan Pharma Achieves 4X Revenue Growth In Q1, Hits $6.8M Mark
No Data